Demonstrate the suitability of an immunomodulator to stimulate the innate immune system to fight the parasitic infection responsible for cutaneous leishmaniasis
current phase of drug development
updated 16 Feb 2023
CpG-D35 (DNDI-2319) is being developed as a combination therapy for the treatment of complicated cutaneous leishmaniasis and post-kala-azar dermal leishmaniasis (PKDL) in partnership with Ajinomoto Bio-Pharma Services (GeneDesign, Inc.) and the University of Tokyo. Leishmania parasites are able to persist in host cells by evading or exploiting immune mechanisms. Modulating the immune response with CpG oligonucleotides may improve the effectiveness of chemotherapies. This project aims to produce an immunomodulator to stimulate the innate immune system and fight parasitic infection as an adjunct to drug therapy.
News & resources
- 3 October 2022 - DNDi 2022 Projects of the Year recognize partners and colleagues for their work in developing new treatments for leishmaniasis
- 28 February 2020 - CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis, PLOS Neglected Tropical Diseases
Get our latest news, personal stories, research articles, and job opportunities.